UCM Stock Overview
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Uscom Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.051 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.044 |
| Beta | -0.82 |
| 1 Month Change | 13.33% |
| 3 Month Change | 2.00% |
| 1 Year Change | -51.43% |
| 3 Year Change | -83.81% |
| 5 Year Change | -78.30% |
| Change since IPO | -97.88% |
Recent News & Updates
Shareholder Returns
| UCM | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 0.5% |
| 1Y | -51.4% | 5.3% | 2.1% |
Return vs Industry: UCM underperformed the Australian Medical Equipment industry which returned 5.3% over the past year.
Return vs Market: UCM underperformed the Australian Market which returned 2.1% over the past year.
Price Volatility
| UCM volatility | |
|---|---|
| UCM Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: Insufficient data to determine UCM's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine UCM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 35 | Rob Phillips | https://www.uscom.com.au |
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices.
Uscom Limited Fundamentals Summary
| UCM fundamental statistics | |
|---|---|
| Market Cap | AU$10.13m |
| Earnings (TTM) | -AU$1.97m |
| Revenue (TTM) | AU$3.25m |
3.1x
P/S Ratio-5.1x
P/E RatioIs UCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UCM income statement (TTM) | |
|---|---|
| Revenue | AU$3.25m |
| Cost of Revenue | AU$344.47k |
| Gross Profit | AU$2.91m |
| Other Expenses | AU$4.88m |
| Earnings | -AU$1.97m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0099 |
| Gross Margin | 89.41% |
| Net Profit Margin | -60.62% |
| Debt/Equity Ratio | 0% |
How did UCM perform over the long term?
See historical performance and comparison